Escudier B - Search Results

1

Therapeutic sequencing in the era of first-line immune checkpoint inhibitor combinations, a novel challenge in patients with metastatic clear-cell renal cell carcinoma.

Flippot R, Gorgeu V, Pujalte M, Colomba E, Alves C, Cerbone L, Carril L, Derosa L, Escudier B, Albigès L. Flippot R, et al. Among authors: escudier b. Bull Cancer. 2022 May;109(2S):2S31-2S38. doi: 10.1016/S0007-4551(22)00236-3. Bull Cancer. 2022. PMID: 35760468 Review.

2

A phase II study of irinotecan in patients with advanced renal cell carcinoma.

Fizazi K, Rolland F, Chevreau C, Droz JP, Mery-Mignard D, Culine S, Escudier B. Fizazi K, et al. Among authors: escudier b. Cancer. 2003 Jul 1;98(1):61-5. doi: 10.1002/cncr.11474. Cancer. 2003. PMID: 12833456 Free article. Clinical Trial.

3

Analysis of the natural killer mediated immune response in metastatic renal cell carcinoma patients.

Gati A, Da Rocha S, Guerra N, Escudier B, Moretta A, Chouaib S, Angevin E, Caignard A. Gati A, et al. Among authors: escudier b. Int J Cancer. 2004 Apr 10;109(3):393-401. doi: 10.1002/ijc.11730. Int J Cancer. 2004. PMID: 14961578 Free article.

4

[Interest of color Doppler ultrasonography to evaluate a new anti-angiogenic treatment with thalidomide in metastatic renal cell carcinoma].

Lassau N, Chawi I, Rouffiac V, Bidault S, Escudier B, Leclère J. Lassau N, et al. Among authors: escudier b. Bull Cancer. 2004 Jul-Aug;91(7-8):629-35. Bull Cancer. 2004. PMID: 15381453 Free article. Clinical Trial. French.

5

Peripheral gammadelta T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma.

Viey E, Laplace C, Escudier B. Viey E, et al. Among authors: escudier b. Expert Rev Anticancer Ther. 2005 Dec;5(6):973-86. doi: 10.1586/14737140.5.6.973. Expert Rev Anticancer Ther. 2005. PMID: 16336088 Review.

6

[New entities in pathological classification and new therapeutic options in renal cell carcinoma].

Bay JO, Penault-Llorca F, Ravaud A, Chevreau C, Négrier S, Escudier B. Bay JO, et al. Among authors: escudier b. Bull Cancer. 2006 Jan;93(1):91-100. Bull Cancer. 2006. PMID: 16455511 Free article. Review. French.

7

Sorafenib in advanced clear-cell renal-cell carcinoma.

Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group. Escudier B, et al. N Engl J Med. 2007 Jan 11;356(2):125-34. doi: 10.1056/NEJMoa060655. N Engl J Med. 2007. PMID: 17215530 Free article. Clinical Trial.

8

Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.

Escudier B, Lassau N, Angevin E, Soria JC, Chami L, Lamuraglia M, Zafarana E, Landreau V, Schwartz B, Brendel E, Armand JP, Robert C. Escudier B, et al. Clin Cancer Res. 2007 Mar 15;13(6):1801-9. doi: 10.1158/1078-0432.CCR-06-1432. Clin Cancer Res. 2007. PMID: 17363536 Clinical Trial.

9

Advanced renal cell carcinoma: current and emerging management strategies.

Escudier B. Escudier B. Drugs. 2007;67(9):1257-64. doi: 10.2165/00003495-200767090-00002. Drugs. 2007. PMID: 17547470 Review.

10

Anti-VEGF therapy for renal cell carcinoma.

Escudier B. Escudier B. Clin Adv Hematol Oncol. 2007 Jul;5(7):530-1. Clin Adv Hematol Oncol. 2007. PMID: 17679926 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

548 results

Search Page